Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCAB with… →

BCAB Key Statistics

As of Sep 4, 2026

Trading

Open: $1.25
Previous Close: $1.30
Day's Range: 1.16–1.39
52-Week Range: 1.07–71.50
Volume: 19.10K
Beta: 0.70

Valuation

Market Cap: $2.89M
P/E Ratio: unprofitable
P/S ratio: 0.34
EPS (ttm): −25.46

Financials (FY)

Revenue (FY): $2.00M−81.82%
Net Income (FY): −$59.61M
Profit margin: 0.00%
Shares Outstanding: 1.67M
1-Year Return: −94.71%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 78.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCAB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+9.64%−42.28%−57.97%−70.18%−75.98%−3.89%−95.35%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−95.35%
2025	−3.89%
2024	−75.98%
2023	−70.18%
2022	−57.97%
2021	−42.28%
2020 (partial year)	+9.64%

As of September 4, 2026.

BCAB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.00M	−$59.61M	−2980.3%
2024	$11.00M	−$69.78M	−634.3%
2023	$0.00	−$123.46M	—
2022	$0.00	−$106.48M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.00M	—	−$59.31M	−$59.61M	−2980.3%
2024	$11.00M	—	−$73.94M	−$69.78M	−634.3%
2023	$0.00	—	−$129.69M	−$123.46M	—
2022	$0.00	—	−$108.14M	−$106.48M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BCAB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	BCAB	Biotechnology median	vs median
P/S ratio	0.34	15.26	0.0x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

BioAtla To Be Delisted From Nasdaq Following Listing Council Decision; Trading Suspension Effective August 31, With Shares Expected To Transition To OTC Markets
Benzinga2026-08-28

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BioAtla, Inc. (BCAB) at $2.89M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 41.

The 52-week range on file runs from $1.07 to $71.50. BCAB last closed at $1.32 on September 4, 2026. That is +$0.02 (+1.54%) against the previous close. The latest close sits 23.36% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.00M. That is −81.82% against the prior fiscal year, when revenue was $11.00M. The same year closed with a net loss of $59.61M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −25.46.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $2.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.34 times revenue. On price-to-sales that is 0 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −94.71%. Measured over 5 years, that is −77.01% a year compounded. The reported beta is 0.7. Daily returns over the trailing 5 years annualize to a volatility of 121.94%.

Growth & Income

No dividend is on file for BCAB.

So far in 2026 the price is −95.35%. Across the complete calendar years on file, 2025 returned −3.89% and 2024 returned −75.98%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

BioAtla, Inc. (BCAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
BioAtla, Inc.	BCAB	$2.89M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. BioAtla, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Visit website →

BioAtla, Inc. (BCAB) Stock Analysis